1. Scrip
  2. >>Business
  3. >>Earnings

Mirati Generates Cautious Optimism With KRAS/PD-1 Combo Data

Adagrasib/Keytruda Show Preliminary ORR Of 71%

 
• By Alaric DeArment

The biotech also provided an update on its pursuit of approval for adagrasib, a KRAS G12C inhibitor that is likely to compete against Amgen’s first-to-market Lumakras.

earnings report
Mirati reported its third quarter earnings, as well as closely watched combination data for its KRAS G12C inhibitor and Merck's Keytruda • Source: Shutterstock

Mirati Therapeutics, Inc. is seeing cautious optimism over long-awaited combination data pairing its KRAS G12C inhibitor adagrasib with a checkpoint inhibitor, as the small patient population makes it difficult to draw firm conclusions. But analysts are keen for any insight as they try to assess how adagrasib could contend with Amgen, Inc.’s currently marketed KRAS G12C inhibitor, Lumakras (sotorasib).

The biotech company announced its third quarter earnings 8 November, reporting revenues from licensing and collaborations of $71.8m, compared with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By Kevin Grogan

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Stock Watch: Q2 Sales Growth Sparks Diverging Reactions To J&J And Novartis

 
• By Andy Smith

With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 
• By Anju Ghangurde

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.

More from Business

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

 
• By Anju Ghangurde

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

Roche, Following Sarepta, Pauses Elevidys Shipments In Certain Countries

 
• By Mandy Jackson

Roche paused shipments of the Duchenne muscular dystrophy gene therapy in countries that reference US FDA approval of Elevidys after the agency asked Sarepta to pause US shipments; it remains available in Japan and Brazil.

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 
• By Alaric DeArment

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.